Buscar por Autor Bogner, J.R.

Ir a: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
O introducir las primeras letras:  
Mostrando resultados 1 a 4 de 4
Fecha de publicaciónTítuloAutor(es)
2012A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityMoyle, G.J.; Andrade-Villanueva, J.; Girard, P.-M.; Antinori, A.; Salvato, P.; Bogner, J.R.; Hay, P.; Santos, J.; Astier, L.; Pans, M.; Balogh, A.; Biguenet, S.; Moyle, G.J., St. Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Girard, P.-M., Departments of Virology and Infectious Diseases, Saint-Antoine Hospital, Assitance-Publique Hopitaux de Paris, Paris, France; Antinori, A., Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy; Salvato, P., Diversified Medical Practices PA, Houston, TX, United States; Bogner, J.R., LMU Medizinische Poliklinik, Munich, Germany; Hay, P., Department of Genitourinary Medicine, St. George's Hospital, London, United Kingdom; Santos, J., Hospital Virgen de la Victoria, M�laga, Spain; Astier, L., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Pans, M., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Balogh, A., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Biguenet, S., Bristol-Myers Squibb Research and Development, Rueil-Malmaison, France
2012A randomized comparative 96-week trial of boosted atazanavir versus continued boosted protease inhibitor in HIV-1 patients with abdominal adiposityMoyle, G.J.; Andrade-Villanueva, J.; Girard, P.-M.; Antinori, A.; Salvato, P.; Bogner, J.R.; Hay, P.; Santos, J.; Astier, L.; Pans, M.; Balogh, A.; Biguenet, S.; Moyle, G.J., St. Stephens Centre, Chelsea and Westminster Hospital, London, United Kingdom; Andrade-Villanueva, J., Hospital Civil de Guadalajara, CUCS, Universidad de Guadalajara, Guadalajara, Mexico; Girard, P.-M., Departments of Virology and Infectious Diseases, Saint-Antoine Hospital, Assitance-Publique Hopitaux de Paris, Paris, France; Antinori, A., Clinical Department, National Institute for Infectious Diseases Lazzaro Spallanzani IRCCS, Roma, Italy; Salvato, P., Diversified Medical Practices PA, Houston, TX, United States; Bogner, J.R., LMU Medizinische Poliklinik, Munich, Germany; Hay, P., Department of Genitourinary Medicine, St. George's Hospital, London, United Kingdom; Santos, J., Hospital Virgen de la Victoria, Málaga, Spain; Astier, L., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Pans, M., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Balogh, A., Bristol-Myers Squibb Research and Development, Bruxelles, Belgium; Biguenet, S., Bristol-Myers Squibb Research and Development, Rueil-Malmaison, France
2013Verxve 144-week results: Nevirapine extended release (nvp xr) qd versus nvp immediate release (ir) bid with ftc/tdf in treatment-naive hiv-1 patientsBrinson, C.; Bogner, J.R.; Nelson, M.; Podzamczer, D.; Quinson, A.M.; Drulak, M.; Andrade-Villanueva, J.; Cahn, P.; Santiago, S.; Gathe, J.; Brinson, C., Central Texas Clinical Research, Austin, TX, United States; Bogner, J.R., University Hospital of Munich, Munich, Germany; Nelson, M., St Stephen's AIDS Trust, London, United Kingdom; Podzamczer, D., Hospital Universitari de Bellvitge, Barcelona, Spain; Quinson, A.M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Andrade-Villanueva, J., Universidad de Guadalajara, Guadalajara, Mexico; Cahn, P., Fundaci�n Husp�d, Buenos Aires, Argentina; Santiago, S., Care Resource, Miami, FL, United States; Gathe, J., Therapeutic Concepts, Houston, TX, United States
2013Verxve 144-week results: Nevirapine extended release (nvp xr) qd versus nvp immediate release (ir) bid with ftc/tdf in treatment-naive hiv-1 patientsBrinson, C.; Bogner, J.R.; Nelson, M.; Podzamczer, D.; Quinson, A.M.; Drulak, M.; Andrade-Villanueva, J.; Cahn, P.; Santiago, S.; Gathe, J.; Brinson, C., Central Texas Clinical Research, Austin, TX, United States; Bogner, J.R., University Hospital of Munich, Munich, Germany; Nelson, M., St Stephen's AIDS Trust, London, United Kingdom; Podzamczer, D., Hospital Universitari de Bellvitge, Barcelona, Spain; Quinson, A.M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Drulak, M., Boehringer Ingelheim Pharmaceuticals, Inc, Ridgefield, CT, United States; Andrade-Villanueva, J., Universidad de Guadalajara, Guadalajara, Mexico; Cahn, P., Fundación Huspéd, Buenos Aires, Argentina; Santiago, S., Care Resource, Miami, FL, United States; Gathe, J., Therapeutic Concepts, Houston, TX, United States